Last reviewed · How we verify
Ornidazole and Sodium Chloride Injection
Ornidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after reduction of its nitro group.
Ornidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after reduction of its nitro group. Used for Anaerobic bacterial infections, Protozoal infections (e.g., trichomoniasis, amebiasis), Surgical prophylaxis for anaerobic infection.
At a glance
| Generic name | Ornidazole and Sodium Chloride Injection |
|---|---|
| Sponsor | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd |
| Drug class | Nitroimidazole antibiotic |
| Target | Bacterial/parasitic DNA |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ornidazole penetrates microbial cells and undergoes reduction of its 5-nitro group by anaerobic metabolism, producing reactive intermediates that damage DNA and inhibit nucleic acid synthesis. This mechanism is effective against anaerobic bacteria and certain protozoa. The sodium chloride component is a physiological saline carrier for intravenous administration.
Approved indications
- Anaerobic bacterial infections
- Protozoal infections (e.g., trichomoniasis, amebiasis)
- Surgical prophylaxis for anaerobic infection
Common side effects
- Metallic taste
- Nausea
- Headache
- Peripheral neuropathy (with prolonged use)
- Allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: